Panorama France HealthTech 2026 's review: a mature, innovative and resilient sector facing a more demanding environment-- An ecosystem of nearly 2,800 companies, driven by innova ...

As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being ...

Missouri S&T’s proposed biochemistry program would combine lab research, data analysis and life sciences to meet growing ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

Biotech funding has been in a down cycle for roughly the past four years. Higher interest rates, tighter capital markets, and ...

Biotech IPOs fell to a decade low in 2025 Investors expect more listings amid easing rate pressure Policy clarity under Trump has reduced worst-case fears Late-stage drug pipelines drawing renewed ...

BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with ...

Institutional and private investors have given the Spanish biotech sector a powerful boost with the closing of a new €126.4 million (US$140 million) venture fund by local firm Ysios Capital. According ...

The biotech sector has been one of the market's laggards for several years now, and 2025 has been no different, at least on ...

Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...